Invicorp (aviptadil/phentolamine mesilate)
/ Regent Pacific Group
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
April 07, 2025
Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction.
(PubMed, J Sex Med)
- "Almost 60% of the participants with refractory ED were successfully managed through the administration of AvP."
Journal • Erectile Dysfunction • Pain
July 26, 2024
Cavernous body auto-injection therapy for erectile dysfunction, Aviptadil/Phentolamine (Invicorp®) – an effective alternative for erectile dysfunction (ED) with an excellent side effect profile
(DGU 2024)
- "Sponsored by Evolan"
Adverse events • Erectile Dysfunction
July 26, 2024
WS02 Cavernous body auto-injection therapy for erectile dysfunction, Aviptadil/Phentolamine (Invicorp®) an effective alternative for erectile dysfunction (ED) with an excellent side effect profile
(DGU 2024)
- "Sponsored by Evolan The introduction of phosphodiesterase inhibitors such as sildenafil and others led to high expectations but high drop-out rates due to effectiveness issues and side effects. The combination of VIP and phentolamine (Invicorp®) showed comparable effectiveness with less pain than alprostadil. Invicorp® could be a better alternative, especially for ED patients after RRP or cystectomy."
Adverse events • Erectile Dysfunction • Pain
April 22, 2024
A comprehensive history of injection therapy for erectile dysfunction, 1982-2023.
(PubMed, Sex Med Rev)
- "After 40 years, self-injection therapy represents the medication with the highest efficacy and reliability rates and remains a viable option for many couples with ED. The history of this therapy is rich."
Journal • Erectile Dysfunction
July 10, 2021
"Thank you for the #expertsummary and your comments on the INVICORP article #EAU21"
(@donwglee)
April 27, 2021
[VIRTUAL] Intracavernosal aviptadil with phentolamine mesylate should be offered for treatment of refractory erectile dysfunction
(EAU 2021)
- No abstract available
Erectile Dysfunction
July 26, 2019
Reflexions on 50 Years of Sexual Medicine in Urology Focusing on Male Sexual Dysfunctions
(PubMed, Aktuelle Urol)
- "Starting with the development of hydraulic penile implants in 1973 meanwhile several effective and well-tolerated conservative treatments such as the PDE-5 inhibitors avanafil, sildenafil, tadalafil and vardenafil, transurethral PGE1 (MUSE) and self-injection therapy with a variety of vasoactive drugs like alprostadil, papaverine/phentolamine (bimix), PGE1/papaverine/phentolamine (trimix/triple drug) or VIP (aviptadil)/phentolamine-Invicorp) have been developed for the treatment of ED. Regarding premature ejaculation (PE) meanwhile with oral dapoxetine and topical lidocaine/prilocaine spray two effective treatment options are officially available which may be combined in men with severe PE and with PDE-5 inhibitors in men with PE and ED. Hormonal disorders such as hypogonadism, hyperprolactinemia and thyroid disorders may be linked to male sexual disorders and successfully treated with T-substitution, prolactin inhibitors or thyroid specific medications.Whereas vascular..."
Journal
1 to 7
Of
7
Go to page
1